---
title: "Lysergide (DT120) in Generalized anxiety disorder: MM-120-101"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: MM-120-101. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Statistical analysis description, and 2 further headings. 33 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence/mm-120-101"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: MM-120-101

<a id="heading-3.1.6"></a>

## 3.1.6 MM-120-101

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Comparison of the phase 2b capsule with the phase 3 orally disintegrating tablet

> “This phase 1 study compared the pharmacokinetic (PK), subjective effect, and safety profiles of the phase 2b capsule formulation at 100µg with a new 100µg orally disintegrating tablet (ODT) formulation that was subsequently included in the phase 3 program.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.1-2"></a>

#### Purpose of the bridging study stated in the annual report

> “In our Phase 2 clinical trials for DT120, we used a formulation of DT120 that did not include ODT technology.”
> “In 2024, we completed a pharmacokinetics”
> “bridging study to support the advancement of the DT120 ODT formulation into pivotal clinical trials, and we are using the DT120 ODT formulation in our Phase 3 clinical trials for GAD and MDD.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Registry record

| Item | Registry record |
| --- | --- |
| Scientific title | “Phase I trial: MM-120-101” |
| IRAS number | “1007602” |
| Sponsor | “Mind Medicine Inc” |
| Countries of recruitment | “United Kingdom” |
| Participating centre | “MAC Clinical Research Liverpool” |
| Participating centre | “MAC Clinical Research Manchester” |
| Date of first enrolment | “13/10/2023” |
| Date of final enrolment | “04/12/2023” |
| Completion date | “19/12/2023” |
| Overall study status | “Deferred” |

Source: [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)

<a id="topic-3.1.6.2-2"></a>

#### Ethics approval

| Item | Research summary |
| --- | --- |
| REC name | “Wales REC 1” |
| REC reference | “23/WA/0112” |
| Date of REC opinion | “1 Sep 2023” |
| REC opinion | “Further Information Favourable Opinion” |

Source: [HRA Phase 1 PK study of MM-120 in healthy volunteers (2023)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-pk-study-of-mm-120-in-healthy-volunteers/)

<a id="topic-3.1.6.2-3"></a>

#### Number of sites

> “This was a phase 1, multicenter (two sites), open-label, randomized, 2-period, 2-sequence, cross-over, within-subject study”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.2-4"></a>

#### Deferred publication of registry details

> “The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.”
> “29/06/2026: The deferral expiry date was changed from 20/11/2026 to 19/12/2028.”

Source: [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Open-label, randomized, two-period crossover design

> “This was a phase 1, multicenter (two sites), open-label, randomized, 2-period, 2-sequence, cross-over, within-subject study designed to compare the plasma PK profile of 2 MM120 formulations in healthy adults aged 18 to 55 years.”
> “All participants received a single dose of each formulation (capsules or ODT) in separate evaluation periods, separated by a 2-week washout period between dosing.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.3-2"></a>

#### Full title of the study

> “A Phase 1, Open-label Study to Compare the Pharmacokinetics of Two Formulations of MM-120 in Healthy Volunteers”

Source: [HRA Phase 1 PK study of MM-120 in healthy volunteers (2023)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-pk-study-of-mm-120-in-healthy-volunteers/)

<a id="topic-3.1.6.3-3"></a>

#### Study schedule

| Period | Quoted study day |
| --- | --- |
| Screening | “-21 to -1” |
| Washout | “2-13” |
| Follow-up | “15-29” |

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

> “Study MM120-101 | ODT-PK Bridging”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.6.3-4"></a>

#### Registry design description

| Item | Registry record |
| --- | --- |
| Study design | “Phase 1 study in 30 healthy volunteers” |
| Primary study design | “Other” |
| Phase | “Phase I” |
| Intervention type | “Drug” |

Source: [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)

<a id="topic-3.1.6.3-5"></a>

#### Assessments: plasma pharmacokinetics, subjective effects, and adverse events

> “Plasma concentrations of MM120 were determined by validated bioanalytical method.”
> “Subjective effects were assessed using the Visual Analogue Scales (VAS) and 5-Dimensional Altered States of Consciousness (5D-ASC) scale, and descriptive statistics were presented for each category.”
> “Adverse events (AEs) were summarized for each treatment group by system organ class and preferred term.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.3-6"></a>

#### Study design as described in the pooled safety analysis

> “Open-label, crossover in healthy volunteers”
> “Single 100-µg ODT or capsule”
> “2-week washout”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Entry criteria

| Criterion | Quoted entry criterion |
| --- | --- |
| Sex | “Men and Women” |
| Age | “Ages 18-55” |
| Health status | “Healthy volunteers” |
| Medications | “No prohibited medications” |

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.6.4-2"></a>

#### Registry eligibility fields

| Item | Registry record |
| --- | --- |
| Participant type | “Healthy volunteer” |
| Age group | “Adult” |
| Sex | “All” |
| Health condition studied | “Healthy volunteers” |

Source: [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Four 25 µg capsules and one 100 µg orally disintegrating tablet, in randomized sequence

> “Participants were randomized equally to receive either four 25-μg MM120 capsules followed by 100μg MM120 ODT or ODT followed by capsules.”
> “MM120 100μg (freebase-equivalent) is considered an acceptable therapeutic dose.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.5-2"></a>

#### Formulations named in the study schematic

> “MM120 Zydis ODT (100 µg)”
> “MM120 Capsule (100 µg)”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Plasma Pharmacokinetic Parameters as the Primary Endpoint

Not applicable.

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Planned sample size

| Item | Registry record |
| --- | --- |
| Target sample size at registration | “30” |

Source: [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)

<a id="topic-3.1.6.7.1-2"></a>

##### Participants randomized and dosed with both formulations

> “A total of 29 participants were randomized, and 24 participants received each MM120 formulation as a single dose.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

> “29 participants total (actual)”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

##### Pharmacokinetic analysis set

> “Company analysis of pharmacokinetic data from Study MM120-101. PK analysis based on n=24 subjects that completed both dosing sessions.”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.6.7.2-2"></a>

##### Analysis methods

> “The PK and analysis of relative bioavailability between the 2 formulations were performed using Phoenix WinNonlin.”
> “Terms used to identify AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA v26.0).”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.7.2-3"></a>

##### Safety analysis set in the pooled safety analysis

> “Phase 1 PK Bioavailability (n = 29)”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

##### Randomized and completing both periods

> “A total of 29 participants were randomized, and 24 participants received each MM120 formulation as a single dose.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Pharmacokinetic comparison: abstract results

> “MM120 ODT showed a faster onset of plasma concentrations than MM120 capsules, retaining similar relative bioavailability for Cmax.”
> “For AUC, the GMR for MM120 ODT was 16% higher compared with MM120 capsules.”
> “The ODT formulation had bioavailability similar to that of the capsule. ODT absorption occurred faster compared with capsules and there was a more rapid onset of acute drug effects in the ODT formulation.”
> “This study demonstrated that 100µg MM120 ODT was an acceptable formulation to take forward in clinical development.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.8.3-2"></a>

##### Pharmacokinetic parameters by formulation

| PK parameter | MM120 capsule | MM120 ODT |
| --- | --- | --- |
| Tmax (hr) | “2.25” | “2.0” |
| Cmax (ng/mL) | “2.63” | “2.68” |
| AUC0-∞ (ng*hr/mL) | “15.7” | “18.7” |
| AUC>1ng/mL (ng*hr/mL) | “9.7” | “12.0” |

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.6.8.3-3"></a>

##### Geometric mean ratios relative to the capsule

| Parameter | Quoted geometric mean ratio |
| --- | --- |
| Cmax | “GMR: 1.02” |
| AUC0-∞ | “GMR: 1.17” |

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.6.8.3-4"></a>

##### Company-derived comparisons and their bases, March 2024

> “50% faster onset of action”
> “17% improved bioavailability”
> “23% increase in AUC at target conc.”
> “Reduced GI side effects”
> “Based on time to reach target concentration of >1 ng/mL.”
> “Based on comparison of geometric mean ratio of total area under the curve.”
> “Based on ratio of mean AUC>1ng/mL. Target concentrations defined as level above which perceptual effects are present.”
> “Based on a comparison between Phase 2b study of MM120 capsules in GAD versus PK bridging study of MM120 ODTs”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

##### Subjective drug effects on visual analogue scales

> “Similar to PK profiles, the VAS scores showed an earlier onset of effects for MM120 ODT compared with capsules.”
> “Maximum drug effect VAS scores were reported at 3 and 4 hours post-dose for participants receiving MM120 ODT or capsules, respectively.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Treatment-emergent adverse events by formulation: abstract

> “Twenty-three (79.3%) and 22 (75.9%) participants reported 69 and 65 TEAEs after receiving MM120 ODT and capsules, respectively.”
> “Of these, participants receiving MM120 ODT compared with capsules reported similar rates of visual hallucinations (58.6 vs 51.7%), euphoric mood (48.3 vs 41.4%), and illusion (20.7 vs 17.2%).”
> “Most TEAEs were mild to moderate after a single dose of both formulations and were consistent with the expected acute effects of MM120.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.8.5-2"></a>

##### Treatment-emergent adverse events in the pooled safety poster

| Measure | Phase 1 PK bioavailability study, DT120 ODT (n = 29) |
| --- | --- |
| Any TEAE | “25 (86.2)” |
| Mild | “15 (51.7)” |
| Moderate | “9 (31.0)” |
| Severe | “1 (3.4)” |

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-3.1.6.8.5-3"></a>

##### Serious adverse events, suicidality, and vital signs across the four pooled studies

> “Across all 4 studies, there were no treatment-related serious adverse events (AEs), hallucinogen persisting perception disorder, or deaths after treatment with DT120”
> “Similarly, there was no worsening of preexisting passive suicidal ideation, no active suicidal ideation or behaviors, and no evidence of session-induced suicidal ideation”
> “Changes in vital signs were not clinically significant”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary

MM-120-101 was an open-label, randomized, two-period crossover study in healthy adults aged 18 to 55 years; it measured plasma pharmacokinetics, subjective effects, and adverse events, and enrolled no participants with GAD. Of 30 planned participants, 29 were randomized and 24 received both formulations; the pharmacokinetic analysis used those 24. Each formulation was given once at 100 µg, so the study does not inform repeated dosing or other dose levels.

Results come from an abstract, company presentations, and a safety analysis across four DT120 studies; publication of the registry record's full details is deferred to 19/12/2028. Sources differ on the pharmacokinetic summary: the abstract reports Cmax as similar, an AUC geometric mean ratio 16% higher with the ODT, and bioavailability similar to the capsule, while a company presentation describes 17% improved bioavailability (a geometric mean ratio of 1.17), a 23% increase in AUC at target concentration, and reduced gastrointestinal side effects based on a comparison between the phase 2b capsule study and this study. Sources also differ on adverse events with the ODT: the abstract reports 23 participants (79.3%) with TEAEs after the ODT, and the pooled safety poster reports 25 (86.2%) in a column labeled DT120 ODT (n = 29). The company's annual report states that the bridging study was completed in 2024, while the registry gives a completion date of 19/12/2023. The annual report states that the change in formulation could cause the product to perform differently, and one author names formulation bridging among the conditions on which adoption will depend.

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf); [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf); [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf); [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603); [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="topic-3.1.6.9-2"></a>

#### Risk stated by the company from the change in formulation

> “This change in formulation could cause DT120 to perform differently, cause unforeseen side effects or affect the results of our Phase 3 clinical trials.”
> “This could delay completion of our Phase 3 clinical trials, require us to conduct additional bridging clinical trials, repeat one or more clinical trials, increase clinical trial costs or delay or prevent the submission, or approval, of one or more NDAs for DT120.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-3.1.6.9-3"></a>

#### Formulation bridging named as a condition for adoption

> “Adoption will depend on full peer-reviewed reporting of the positive Voyage and Panorama phase 3 topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable monitored-care model.”

Source: [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
